Poor Prognosis Acute Myelogenous Leukemia

References

• Preisler H. D., Lyman G. H. Acute myelogenous Leukemia subsequent to therapy for a different neoplasm: Clinical features and response to therapy. Amer. J. Hematol 1977; 3: 209–218
   PubMed Web of Science ®Google Scholar
• Preisler H. D. The treatment of Acute nonlymphocytic leukemia. Blood Rev. 1987; 1: 97–105
   PubMedGoogle Scholar
• Gajewski J. L., Ho W. G., Nimer S. D., Hirji K. R., Gekelman L., Jacobs A. D., Champlin R. E. Efficacy of intensive chemotherapy for acute myelogenous Leukemia associated with a preleukemic syndrome. J. Clin. Oncol. 1989; 7: 1637–1645
   PubMed Web of Science ®Google Scholar
• Hoyle C. F., de Bostos M., Wheatley K., Scherrington P. D., Fischer P. J., Ress J. K., Grey R., Hayhow F. G. AML associated with a previous cytotoxic therapy, MDS, or myeloproliferative disorder: Results from the MRC's 9th AML Trial. Brit. J. Haem. 1989; 72: 45–52
   PubMed Web of Science ®Google Scholar
• Kahn S. B., Begg C. B., Mazza J. J., Bennett J. M., Bonner H., Glick J. H. Full dose vs attenuated dose daunomycin, cytosine arabinoside and 6-thioguanine in the treatment of acute nonlymphocytic Leukemia in the elderly. J. Clin. Oncol. 1984; 2: 865–870
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Davis R. B., Kirschner J., Du Pre E., Richards F., Hoagland H. C., Kopel S., Levy R. N., Carey R., Schulman P., Gottleib A., McLntyre O. R. Comparison of three remission induction regimens and the two post-induction strategies for the treatment of ANLL. A CALGB study. Blood 1987; 69(5)1441–-1449
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Raza A., Barcos M., Azarnia N., Larson R., Walker I., Browman M., Grunwald H., D'Arrigo P., Doeblin T., Bloom M., Stein A., Logue C., Goldberg J., Kiershner J., Gottlieb A., Bennett J. High dose cytosine arabinoside as the initial treatment of poor risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup study. J. Clin. Oncol. 1987; 5: 75–82
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Larson R. A., Raza A., Browman G., Goldberg J., Vogler R., Day R., Gottlieb A., Vardiman J. W., Bennett J., Kukla C., Grunwald H. The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukemia: Response to treatment and treatment failure. Br. J. Haematol. 1991; 79: 390–397
   PubMed Web of Science ®Google Scholar
• Hamblin T. The treatment of acute myeloid Leukemia preceded by a myelodysplastic syndrome. Leuk. Res. 1992; 16: 101–108
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Jasperse D. M., Simon R., Friedman M. A. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic Leukemia and myelodysplastic syndromes. J. Clin. Oncol. 1986; 4: 1857–1864
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Raza A., Larson R., Browman G., Goldberg J., Grunwald H., Vogler R., Bennett J., Gottlieb A., D'Arrigo P. Limited efficacy of a four day course of high dose cytosine arabinoside in the treatment of poor risk patients with acute nonlymphocytic leukemia. Cancer Chemother. Pharmacol. 1986; 18: 257–260
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Raza A., Barcos M., Azarnia N., Larson R., Browman G., Walker I., Grunwald H., D'Arrigo P, Stein A., Bloom M., Goldberg J., Gottlieb A., Bennett J., Kirshner J., Priore R. High dose cytosine arabinoside in the treatment of preleukemic disorders: a Leukemia Intergroup study. Amer. J. Hematol. 1986; 23(2)131–-134
   PubMed Web of Science ®Google Scholar
• Preisler H. D. Failure of remission induction in acute myelocytic leukemia. Med. Pediatr. Oncol. 1978; 4: 275–276
   PubMedGoogle Scholar
• Preisler H. D. Treatment failure in AML. Blood Cells 1982; 8: 585–602
   PubMedGoogle Scholar
• Preisler H. D., Raza A., Larson R., Goldberg J., Tricot G., Carey M., Kukla C. Some reasons for the lack of progress in the treatment of acute myelogenous leukemia. Leuk. Res. 1991; 15(9)773–-780
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Keating M. J., Walters R. S., Smith T. L., Cork A., McCredie K. B., Freireich E. J. Therapy related Leukemia and myelodysplastic syndrome: clinical, cytogenetic and prognostic features. J. Clin. Oncol. 1986; 4: 1748–1757
   PubMed Web of Science ®Google Scholar
• Truong L. D., Saleem A., Schwartz M. R. Acute myelofibrosis. A report of four cases and review of the literature. Medicine 1987; 63: 182–187
   Google Scholar
• Wolf J. L., Spruce W. E., Bearman R. M., et al. Reversal of acute (“malignant”) myelosclerosis by allogeneic bone marrow transplantation. Blood 1982; 59: 191–193
   PubMed Web of Science ®Google Scholar
• Smith J. W., Shulman H. W., Fefer A., Buckner C. D. Bone marrow transplantation for acute myelosclerosis. Cancer 1981; 48: 2198–2203
   PubMed Web of Science ®Google Scholar
• Sargur M., Buckner C. D., Appelbaum F. R., Stewart P., Deeg H. J., Weiden F. P., Sullivan K. M., Fefer A., Thomas E. D. Marrow transplantation for acute nonlymphocytic Leukemia following therapy for Hodgkin's disease. J. Clin. Oncol 1987; 5(5)731–-734
   PubMed Web of Science ®Google Scholar
• Geller R., Vogelsang G., Wingard J., Yeager A., Burns W., Santos G., Saral R. Successful marrow transplantation for acute myelocytic Leukemia following therapy for Hodgkin's disease. J. Clin. Oncol. 1988; 6(10)1558–-1561
   PubMed Web of Science ®Google Scholar
• O'Donnell M. R., Nademanee A. P., Synder D. S., Schmidt G. M., Parker P. M., Bierman P. J., Fahey J. L., Stein A. S., Krance R. A., Stock A. D., Forman S. J., Blume K. G. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J. Clin. Oncol. 1987; 5(11)1822–-1826
   PubMed Web of Science ®Google Scholar
• Appelbaum F. R., Storb R., Ramberg R. E., Schulman H. M., Buckner C. D., Clift R. A., Deeg H. J., Fefer A., Sanders J., Self S., Singer J., Stewart P., Sullivan K., Witherspoon R., Thomas E. D. Treatment of preleukemic syndromes with marrow transplantation. Blood 1987; 69: 92–96
   PubMed Web of Science ®Google Scholar
• Appelbaum F. R., Barrall J., Storb R., Fisher L. D., Schoch G., Ramberg R. E., Shulman H., Anasetti C., Bearman S. I., Beatty P. Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Ann. Int. Med. 1990; 112(8)590–-597
   PubMed Web of Science ®Google Scholar
• De-Witte T., Zwaan F., Hermans J., Vernant J., Kolb H., Vossen J., Lonnqvist B., Beelen D., Ferrant A., Gmur J. Allogeneic bone marrow transplantation for secondary Leukemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br. J. Haematol. 1990; 74(2)151–-155
   PubMed Web of Science ®Google Scholar
• Gajewski J. L., Ho W. G., Feig S. A., Hunt L., Kaufman N., Champlin R. E. Bone marrow transplantation using unrelated donors for patients with advanced Leukemia or bone marrow failure. Transplantation 1990; 50(2)244–-249
   PubMed Web of Science ®Google Scholar
• Gorin N. C., Labopin M., Meloni G., Korbling M., Carella A., Herve P., Burnett A., Rizzoli V., Alessandrino E. P., Bjorkstrand B. Autologous bone marrow transplantation for acute myeloblastic Leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT). Leukemia 1991; 5(10)896–-904
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Bennett J. M., Vardiman J. W., for, the Leukemia Intergroup.Unpublished observations
   Google Scholar
• Vardiman J. W., Bennett J. M., Larson R. A., Mick R., Preisler H. D. Significance of post-chemotherapy dysplasia (PCD) in marrow specimens of patients treated for AML with myelodysplasia or myelodysplastic syndrome (MDS): a Leukemia Intergroup (LIG) study. 1991, Submitted to Acad. Pathology September
   Google Scholar
• Raza A., Preisler H. D., Li Y. Q., Larson R., Goldberg J., Browman G., Bennett J., Grunwald H., Vogler R., Kukla C. Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia. Amer. J. Hematol., in press
   Web of Science ®Google Scholar
• Preisler H. D., Raza A., Larson R., LeBeau M., Browman G., Goldberg J., Grunwald H., Vogler R., Verkh L., Singh P., Block A. M., Sandberg A. Proto-oncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: a Leukemia Intergroup Pilot study. Blood 1989; 73: 255–262
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Raza A., Larson R., Goldberg J., Tricot G., Browman G., Bennett J., Siegrist C., Pancoast J., Gaskins F., Li Y. Q. FMS expression is highly predictive of treatment outcome in standard risk newly diagnosed patients with acute myelocytic leukemia. MYC and IL1b˜ expression are not. Submitted to. Br. J. Haematol. 1992, February
   Google Scholar
• Sato H., Preisler H. D., Day R., Raza A., Larson R., Browman G., Goldberg J., Vogler R., Grunwald H., Gottlieb A., Bennett J., Gottesman M., Pastan I. MDR, transcript levels as an indication of resistant disease in acute nonlymphocytic leukemia. Br. J. Haematol. 1990; 75(7)340–-345
   PubMed Web of Science ®Google Scholar
• Sato H., Gottesman M. M., Goldstein L. J., Pastan I., Block A. M., Sandberg A. A., Priesler H. D. Expression of the multidrug resistance gene in myeloid leukemias. Leuk. Res. 1990; 14(1)11–-21
   PubMed Web of Science ®Google Scholar
• Liu E. T. The role of ras gene mutations in myeloproliferative disorders. Clin. Lab. Med. 1990; 10: 797–807
   PubMed Web of Science ®Google Scholar
• Preisler H. D. A hypothesis regarding the development of acute myeloid Leukemia from preleukemic disorders: the role of proto-oncogenes. Cancer Genet. Cylogenet. 1988; 32: 133–142
   PubMed Web of Science ®Google Scholar
• Raza A., Preisler H. D., Lampkin B., Lykins J., Kukla C., Gartside P., Sheikh Y., Yousuf N., White L. M., Barcos M., Bennett J., Browman G., Goldberg J., Grunwald H., Larson R., Vardiman J., Vogler R. Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia. Amer. J. Hematol., in press
   Google Scholar
• Gao X. Z., Yin M., Wang X., Raza A., Preisler H. D. Effects of rhGM-CSF on leukemic cell proliferation and on the incorporation of cytosine arabinoside into DNA. Cell. Biochem. and Function 1991; 9: 155–161
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Raza A. Alteration of the proliferative rate of acute myelogenous Leukemia cells in vivo in patients. Blood 1992; 80: 1–4
   PubMedGoogle Scholar
• Preisler H. D., Epstein J., Barcos M., Priore R., Browman G., Vogler R., Grunwald H., Brennan J., Goldberg J., Chervenick P., Miller K., Larson R. Prediction of response of acute nonlymphocytic Leukemia to therapy with “high dose” cytosine arabinoside. Br. J. Haematol. 1984; 58(1)19–-32
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Raza A., Kukla C., Larson R., Goldberg J., Browman G. IL-1b˜ expression and treatment outcome in acute myelogenous Leukemia (AML). Blood 1991; 78(3)849–-850
   PubMed Web of Science ®Google Scholar
• Yin M., Gopal V., Banavali S. D., Priesler H. D. Effects of an IL-lb˜ receptor antagonist on acute myeloid Leukemia cells. Leukemia 1992; 6: 898–901
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Gopal V., Banavali S. D., Finke D., Bokhari S. A. J. Multiparameter assessment of the cell cycle effects of bioactive and cytotoxic agents. Cancer Res. 1992; 52: 1–7
   PubMed Web of Science ®Google Scholar
• Espinoza-Delgado I., Longo D. L., Gusella G. L., Varesio L. IL-2 enhances c-fms expression in human monocyte. J. Immunol. 1990; 145: 1137–1143
   PubMed Web of Science ®Google Scholar
• Koeffler H. P., Amatruda T., Ikekawa N., Kobayashi Y., DeLucca H. F. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues. Cancer Res. 1984; 44: 5624–5628
   PubMed Web of Science ®Google Scholar